Continuing Education

The 2026 Multidisciplinary Radiopharmaceutical Therapy Symposium is a two-day meeting featuring interactive and case-based educational sessions that focus on the evolving utilization of and advancements in radiopharmaceuticals in the treatment of cancer and other indications. The program will include oral abstract presentations showcasing recent clinical and translational research, program models and best practices as well as digital poster sessions, clinical trials in progress and a robust multidisciplinary educational agenda dedicated to the evolving field of radiopharmaceutical therapy (RPT).

Upon completion of this live activity, attendees should be able to do the following:

• Understand the business case for starting a radiopharmaceutical therapy program.
• Design effective multidisciplinary coordination pathways between nuclear medicine, oncology, urology, endocrinology, radiology, and referring providers to optimize patient outcomes.
• Identify best practices in revenue cycle management specific to theranostics, including managing prior authorizations and payer communication.
• Develop and apply continuous audit and quality assessment processes to monitor program success, compliance and operational improvements.
• Recognize emerging considerations such as staffing models, training needs and patient experience metrics that contribute to long-term program sustainability.
• Understand basic radiobiological principles of various forms of radiopharmaceuticals. 
• Discuss complex cases and clinical challenges in radiopharmaceutical therapy and how to best utilize current knowledge for decision making.
• Identify clinical indications and therapy-specific management for RPTs that are currently approved for clinical use.
• Outline the regulatory requirements and application process to obtain AU status.
• Describe the basic principles of RPT dosimetry. 

This educational forum has been designed to narrow the competency gaps of: patient care, medical knowledge, practice-based learning and improvement, interpersonal skills and communication, professionalism, systems-based practice, patient-centered care, work in interdisciplinary teams, employing evidence-based practice, applying quality improvement, utilizing informatics, commitment to lifelong learning, cognitive expertise, evaluation of performance in practice, roles/responsibilities, interprofessional communication and teams and teamwork.

These are 17 of the 19 core competencies embraced by the American Board of Medical Specialties, the Accreditation Council for Graduate Medical Education, the Institute of Medicine, the American Board of Radiology and the Accreditation Council for Continuing Medical Education.

This meeting was designed to meet the interests of medical oncologists, radiation oncologists, physicists, nurses, diagnostic radiologists,  radiation therapists, radiation dosimetrists, specialists, nuclear physicians and practice administrators.

ASTRO is an accredited provider of continuing medical education. Since our accreditation is important to us, we plan activities that are compliant with the ACCME, and the content or format of CME activities and related materials will promote improvements or quality in health care and not a specific proprietary business interest or commercial bias. Planning Committee members and speakers are required to disclose the existence of any financial or other relationship with the manufacturer(s) of any commercial product(s) or provider(s) of any commercial services discussed in an educational presentation.

Any conflicts of interest are resolved prior to participation. In addition to written disclosure, presenters will disclose any vested interest or their intention to discuss off-label use of pharmaceuticals or devices, if applicable, to the audience at the beginning of their presentation and in accordance with the Accreditation Council for Continuing Medical Education standards and the Food and Drug Administration requirements.

Disclaimer
ASTRO is committed to the free exchange of medical education. Inclusion of any presentation in this program, including presentations of off-label uses, does not imply an endorsement by ASTRO of the uses, products or techniques presented.

In an effort to increase transparency and easy access to all disclosures, faculty, committee and planner disclosure information will be available online for the 2026 Multidisciplinary Radiopharmaceutical Therapy Symposium. In addition, disclosure slides will be shown at the beginning of each session. Disclosure information will not be printed in paper versions of the meeting materials.